2004 MacLean-Mueller prize enteral or parenteral nutrition for severe pancreatitis: a randomized controlled trial and health technology assessment

• Published in: Canadian Journal of Surgery Vol. 48; no. 4; pp. 298 - 306
• Main Authors: Louie, Brian E, Noseworthy, Tom, Hailey, David, Gramlich, Leah M, Jacobs, Philip, Warnock, Garth L
• Format: Journal Article
• Language: English
• Published: Canada CMA Impact Inc 01.08.2005; CMA Impact, Inc; Canadian Medical Association
• Subjects: Acute Disease; Adult; Aged; Awards and Prizes; C-Reactive Protein - immunology; Care and treatment; Cost effectiveness; Cost-Benefit Analysis; Diet therapy; Enteral feeding; Enteral Nutrition - economics; Fasting; Female; Humans; Male; Methods; Middle Aged; Nutrition; Original; Pancreas diseases; Pancreatitis; Pancreatitis - economics; Pancreatitis - etiology; Pancreatitis - immunology; Pancreatitis - therapy; Parenteral feeding; Parenteral Nutrition - economics; Parenteral therapy; Patients; Safety; Technology Assessment, Biomedical; Treatment Outcome; Tube feeding; Canada
• ISSN: 0008-428X; 1488-2310

The optimal route of nutrition in severe pancreatitis is controversial. Parenteral nutrition (PN) is preferred, but enteral nutrition (EN) promises to attenuate inflammation and prevent sepsis. We hypothesized that EN was at least equivalent to PN in reducing inflammation, providing effective nutrition and being cost-effective. We conducted a randomized controlled trial comparing PN to EN in pancreatitis in an academic, multi-institutional, tertiary care health system. We screened 728 consecutive patients. Twenty-eight patients with a Ranson's score greater than 2 who did not tolerate clear fluids 4 days after admission were randomized: 18 to PN and 10 to EN. Both groups were provided daily 105 kJ (25 kcal)/kg and 1.5 g/kg of protein, respectively, until they could tolerate a regular diet. C-reactive protein in EN patients was reduced by 50% 5 days faster than PN patients (Wilcoxon test, p = 0.09). Both groups received a similar number of kilojoules and achieved near normal prealbumin and 24-hour urinary nitrogen values. Neither regimen caused a change in cholecystokinin levels. Overall mortality was 4.9% (3 patients in the PN group). In 5 patients (4 PN, 1 EN) there were infected pancreatic collections. Nine EN patients dislodged the nasojejunal tube. EN had an average cost of dollar 1375 per patient compared with dollar 2608 for PN (p = 0.08). After sensitivity analysis, EN cost dollar 957 compared with dollar 2608 for PN (p = 0.03). EN or PN is safe and provides adequate nutrition in severe pancreatitis. EN shows a trend toward faster attenuation of inflammation, with fewer septic complications and is the dominant therapy in terms of cost-effectiveness. This study favours EN for nutritional support in severe pancreatitis.